公开(公告)号：US20140065191A1

公开(公告)日：2014-03-06

申请号：US13762792

申请日：2013-02-08

Applicant: Neeta GUPTA ,  Simrata BEDI ,  Jyoti SRIVASTAVA ,  Vinod Kumar ARORA ,  Manisha PANDYA ,  Vyas M. SHINGATGERI ,  Jaiprakash Jaysingrao BHELONDE ,  Monika OBRAH ,  Sanjay Kumar SHARMA ,  Rajinder K. JALALI ,  Sudershan Kumar ARORA

Inventor： Neeta GUPTA ,  Simrata BEDI ,  Jyoti SRIVASTAVA ,  Vinod Kumar ARORA ,  Manisha PANDYA ,  Vyas M. SHINGATGERI ,  Jaiprakash Jaysingrao BHELONDE ,  Monika OBRAH ,  Sanjay Kumar SHARMA ,  Rajinder K. JALALI ,  Sudershan Kumar ARORA

IPC: A61K9/14 ,  A61K31/155 ,  A61K31/555

CPC classification number: A61K9/14 ,  A61K9/0014 ,  A61K31/155 ,  A61K31/555 ,  A61K31/635 ,  A61K33/38 ,  A61K2300/00

Abstract: The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Abstract translation: 本发明涉及用于人类或动物的烧伤治疗和微生物感染的局部药物组合物。 药物组合物包含0.1％w / w至1.0％w / w的抗微生物药物，即磺胺嘧啶银和0.2％w / w防腐剂，即葡萄糖酸氯己定，其中磺胺嘧啶磺胺为纳米形式。

公开(公告)号：US20090042821A1

公开(公告)日：2009-02-12

申请号：US11914867

申请日：2006-05-18

Applicant: Arno Appavoo Enose ,  Harish Kumar Madan ,  Sumit Madan ,  Anupam Trehan ,  Puneet Tyagi ,  Vinod Kumar Arora

Inventor： Arno Appavoo Enose ,  Harish Kumar Madan ,  Sumit Madan ,  Anupam Trehan ,  Puneet Tyagi ,  Vinod Kumar Arora

IPC: A61K31/70 ,  A61K31/343 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61P33/02 ,  A61K31/4709 ,  A61K31/36 ,  A61K31/4706 ,  A61K31/65

CPC classification number: A61K45/06 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K9/4866 ,  A61K31/335 ,  A61K31/357 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/498 ,  C07D323/02 ,  Y02A50/411 ,  A61K2300/00

Abstract: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.

Abstract translation: 本发明的领域涉及包含螺或脱甲基-1,2,4-三恶烷抗疟药物或其药学上可接受的盐，前药和类似物的稳定剂型及其制备方法。 剂型的含水量不超过6.5％w / w。

公开(公告)号：US06565877B1

公开(公告)日：2003-05-20

申请号：US09587535

申请日：2000-06-05

Applicant: Gour Mukherji ,  Sandhya Goel ,  Vinod Kumar Arora

Inventor： Gour Mukherji ,  Sandhya Goel ,  Vinod Kumar Arora

IPC: A61K914

CPC classification number: A61K9/1635 ,  A61K9/1652

Abstract: A taste masked composition which comprises a bitter tasting drug, a combination of two enteric polymers comprising, a methacrylic acid copolymer and a phthalate polymer is described. The composition of the present invention is prepared by dissolving the active ingredient, the methacrylic acid copolymer and the phthalate polymer in a solvent and recovering the composition from the solution thereof.

Abstract translation: 描述了包含苦味药物，包含甲基丙烯酸共聚物和邻苯二甲酸酯聚合物的两种肠溶性聚合物的组合的掩味组合物。 通过将活性成分，甲基丙烯酸共聚物和邻苯二甲酸酯聚合物溶解在溶剂中并从其溶液中回收组合物制备本发明的组合物。

公开(公告)号：US20220306465A1

公开(公告)日：2022-09-29

申请号：US17702721

申请日：2022-03-23

Applicant: Vinod Kumar Arora

Inventor： Vinod Kumar Arora

IPC: C01B3/38 ,  B01J19/24

Abstract: This disclosure relates installed or new synthesis gas (Syngas) production units and potential modifications to those units to reduce the firing requirements and significant emissions of CO2 from those units with affordable capital expenditures.

公开(公告)号：US11131486B2

公开(公告)日：2021-09-28

申请号：US16380127

申请日：2019-04-10

Applicant: Vinod Kumar Arora

Inventor： Vinod Kumar Arora

IPC: F25B29/00 ,  C01C1/04 ,  F25B7/00

Abstract: An improved performance ammonia plant system utilizing both a direct and indirect chilling of the compressed process air train using a single or multistage chilling system integrated with the ammonia plant ammonia compression train to increase process air flow to the secondary ammonia reformer of the ammonia plant.

公开(公告)号：US08778893B2

公开(公告)日：2014-07-15

申请号：US13500365

申请日：2010-10-04

Applicant: Jiachang Gong ,  Lisa J. Christopher ,  Vinod Kumar Arora

Inventor： Jiachang Gong ,  Lisa J. Christopher ,  Vinod Kumar Arora

IPC: C07H15/26 ,  C07D487/04

CPC classification number: C07D487/04 ,  C07H15/26

Abstract: The present invention is directed to metabolites of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of cancer.

Abstract translation: 本发明涉及（R）-1-（4-（4-氟-2-甲基-1H-吲哚-5-基氧基）-5-甲基吡咯并[2,1-f] [1,2， 4]三嗪-6-基氧基）丙-2-醇，式（I）化合物，其药物组合物，以及使用代谢物和药物组合物治疗癌症的方法。

公开(公告)号：US20130177520A1

公开(公告)日：2013-07-11

申请号：US13519025

申请日：2010-12-23

Applicant: Vasu Kumar Kakumanu ,  Shashikanth Isloor ,  Vinod Kumar Arora

Inventor： Vasu Kumar Kakumanu ,  Shashikanth Isloor ,  Vinod Kumar Arora

IPC: A61K47/48

CPC classification number: A61K47/585 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/427 ,  A61K31/4418 ,  A61K31/495 ,  A61K31/513 ,  A61K31/52

Abstract: The present invention relates to taste masked dosage forms of bitter tasting anti-retroviral drugs comprising a complex of the said anti-retroviral drug and an ion-exchange resin and one or more of other pharmaceutically acceptable excipients. It further relates to the processes for the preparation thereof.

Abstract translation: 本发明涉及苦味抗逆转录病毒药物的掩味剂，其包含所述抗逆转录病毒药物和离子交换树脂与一种或多种其它可药用赋形剂的复合物。 它还涉及其制备方法。

公开(公告)号：US08664265B2

公开(公告)日：2014-03-04

申请号：US13183119

申请日：2011-07-14

Applicant: Arno Appavoo Enose ,  Harish Kumar Madan ,  Sumit Madan ,  Anupam Trehan ,  Puneet Tyagi ,  Vinod Kumar Arora

Inventor： Arno Appavoo Enose ,  Harish Kumar Madan ,  Sumit Madan ,  Anupam Trehan ,  Puneet Tyagi ,  Vinod Kumar Arora

IPC: A61K31/357 ,  C07D493/20

CPC classification number: A61K45/06 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K9/4866 ,  A61K31/335 ,  A61K31/357 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/498 ,  C07D323/02 ,  C07D493/20 ,  A61K2300/00

Abstract: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.

Abstract translation: 本发明的领域涉及包含螺或脱甲基-1,2,4-三恶烷抗疟药物或其药学上可接受的盐，前药和类似物的稳定剂型及其制备方法。 剂型的含水量不超过6.5％w / w。

公开(公告)号：US20130267490A1

公开(公告)日：2013-10-10

申请号：US13814086

申请日：2011-07-21

Applicant: Neeta Gupta ,  Simrata Bedi ,  Jyoti Srivastava ,  Vinod Kumar Arora

Inventor： Neeta Gupta ,  Simrata Bedi ,  Jyoti Srivastava ,  Vinod Kumar Arora

IPC: A61K31/555 ,  A61K31/155

CPC classification number: A61K31/555 ,  A61K9/0014 ,  A61K9/107 ,  A61K31/155 ,  A61K31/635 ,  A61K33/38 ,  A61K45/06 ,  A61K47/06 ,  A61K47/10 ,  A61K47/32 ,  A61K2300/00

Abstract: The invention relates to an improved topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate; wherein silver sulfadiazine is in nanonized form.

Abstract translation: 本发明涉及用于人类或动物的烧伤治疗和微生物感染的改进的局部药物组合物。 药物组合物包含0.1％w / w至1％w / w的抗微生物药物，即磺胺嘧啶银和0.2％w / w防腐剂，即葡萄糖酸洗必太酯; 其中磺胺嘧啶银是纳米形式。

公开(公告)号：US20120196814A1

公开(公告)日：2012-08-02

申请号：US13500365

申请日：2010-10-04

Applicant: Jiachang Gong ,  Lisa J. Christopher ,  Vinod Kumar Arora

Inventor： Jiachang Gong ,  Lisa J. Christopher ,  Vinod Kumar Arora

IPC: A61K31/706 ,  A61P35/00 ,  A61K31/53 ,  C07D487/04 ,  C07H15/26

CPC classification number: C07D487/04 ,  C07H15/26

Abstract: The present invention is directed to metabolites of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of cancer.

Abstract translation: 本发明涉及（R）-1-（4-（4-氟-2-甲基-1H-吲哚-5-基氧基）-5-甲基吡咯并[2,1-f] [1,2， 4]三嗪-6-基氧基）丙-2-醇，式（I）化合物，其药物组合物，以及使用代谢物和药物组合物治疗癌症的方法。